Pierre Fabre and the EspeRare Foundation administer investigational treatment to first patient in EDELIFE clinical trial for rare genetic disease, XLHED
Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields.
![Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets](https://mma.prnewswire.com/media/1916090/Pierre_Fabre_Gennisium__Logo.jpg?p=facebook)